Related Experiment Videos

[Screening and treatment of hyperlipidemias in Israel]

E Sehayek1, S Eisenberg

  • 1Lipid and Atherosclerosis Research Institute, Haim Sheba Medical Center, Tel Hashomer.

Harefuah
|May 1, 1995
PubMed

Insights

This study found that while lipid testing and hyperlipidemia treatment increased with cardiovascular disease severity, overall rates remained lower than expected across all patient groups. Combined hypercholesterolemia and hypertriglyceridemia were most common, with statins and fibric acid derivatives frequently used.

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Public Health

Context:

  • Hyperlipidemias are a significant risk factor for cardiovascular disease (CVD).
  • The Israel Atherosclerosis Society has established screening and treatment guidelines.
  • Primary care physicians' practices regarding lipid management were assessed.

Purpose:

  • To evaluate the frequency of plasma lipid testing and hyperlipidemia treatment in primary care settings.
  • To compare lipid management practices across different patient risk categories, from those without risk factors to post-surgical patients.

Summary:

  • A survey of 2015 adult patients revealed that lipid determinations and drug therapy for hyperlipidemia increased with CVD severity.
  • Despite guidelines, lipid testing rates were lower than expected in all patient groups.
  • Combined hypercholesterolemia and hypertriglyceridemia were the most prevalent metabolic issues, with statins and fibric acid derivatives being common treatments.

Impact:

  • Highlights potential gaps in adherence to hyperlipidemia screening and treatment guidelines within primary care.
  • Informs strategies to improve cardiovascular risk management through better lipid control.
  • Underscores the need for consistent application of evidence-based practices for metabolic disorders.

Related Concept Videos